T cells use the T cell antigen-receptor (TCR) to recognize their antigens, which are often in the form of peptides bound to major histocompatibility complex molecules (MHC), also called HLA (human ...

Containing mutations in the MHC α3 domain that ablate CD8 binding; can be used to quantitate and to sort CD8-independent T cells. Developing high-affinity soluble antibody molecules endowed with a TCR ...

The adaptive immune system depends on the ability to assemble rearranged genes for both the T-cell receptor (TCR ... within the MHC code for human leukocyte antigens, or HLA, two molecular ...

TScan Therapeutics is developing TSC-101 and multiplex TCR-Ts for cancer treatment. See why TCRX stock holds potential with ...

Unlike CAR-T therapy, which is limited to surface antigens, TCR therapy can recognize intracellular tumor-associated antigens presented by major histocompatibility complex (MHC) molecules ...

A TCR genetically engineered to bind specific peptide-HLA complexes can improve targeting specificity. 8 (6) Soluble TCR and TCR mimics are small proteins that bind peptides and engage with the CD3ε ...

Medigene and EpimAb Biotherapeutics have signed a co-development agreement involving T cell receptor (TCR)-guided T cell ... cancer cells by peptide-human leukocyte antigen (HLA) complexes.

Diabetes. 2008;57(11):2872-2882. In summary, it is reasonable to hypothesize that the process of antigenic and epitope spreading is applicable to autoreactive T-cell responses, which can kill ß ...

Unlike CAR-T therapy, which is limited to surface antigens, TCR therapy can recognize intracellular tumor-associated antigens presented by major histocompatibility complex (MHC) molecules, expanding ...